About Endpoint Outcomes
Endpoint Outcomes is a Healthcare company based in Boston (United States) founded in 2012, and was acquired by Lumanity in June 2022. Clinical development and regulatory consulting services for biopharma are provided. Its chief executive, as recorded, is Christopher Evans. Its focus areas include Biopharma Outsourcing, Consulting and Diversified. Its competitors include Indegene, IntegriChain and ClearView Healthcare Partners; 2 of its 3 listed competitors have raised funding.
Company details
Endpoint Outcomes was founded in 2012 and is headquartered in Boston, United States. Consulting services focused on clinical development, outcome validation, regulatory strategy, and related areas are delivered to clients in the biopharmaceutical sector. Operations emphasize support for drug development processes, ensuring compliance and efficacy in therapeutic advancements. Expertise is applied across various stages of biopharma projects to facilitate informed decision-making.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website endpointoutcomes.com
- Social LinkedIn
- Acquired by Lumanity (Jun 2022)
Investors in Endpoint Outcomes
Endpoint Outcomes has secured backing from 1 investor. Prominent investors backing the company include Lumanity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Film production services are provided by Lumanity from London. | 2006 | lumanity.com | London, United Kingdom |
Investor details for Endpoint Outcomes
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Endpoint Outcomes
1 people are tracked at Endpoint Outcomes (1 in leadership).
| Name | Role | Group |
|---|---|---|
Christopher Evans | CEO | Leadership |
Complete people profiles for Endpoint Outcomes
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Endpoint Outcomes
2 dated milestones of Endpoint Outcomes across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Endpoint Outcomes is founded.
- Exit Acquired by Lumanity.
Competitors of Endpoint Outcomes
Endpoint Outcomes has 3 listed competitors in our database, 2 of them funded. They include Indegene, IntegriChain and ClearView Healthcare Partners.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indegene.com | 1998 | Princeton, United States | $220M | 350 | Suite solutions are provided for payers and healthcare providers. | |
| integrichain.com | 2005 | Philadelphia, United States | $2M | 320 | Inventory, order and customer relationship management solution for life science suppliers. | |
| clearviewhcp.com | 2008 | Newton, United States | 381 | Strategic consulting services are provided to life sciences companies. |
Detailed competitors of Endpoint Outcomes
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Endpoint Outcomes (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Endpoint Outcomes
Complete news archive for Endpoint Outcomes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Endpoint Outcomes
Endpoint Outcomes was founded in 2012.
Endpoint Outcomes is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Christopher Evans is the CEO of Endpoint Outcomes, as recorded in our data.
Endpoint Outcomes was founded in 2012 and is headquartered in Boston, United States. Consulting services focused on clinical development, outcome validation, regulatory strategy, and related areas are delivered to clients in the biopharmaceutical sector. Operations emphasize support for drug development processes, ensuring compliance and efficacy in therapeutic advancements. Expertise is applied across various stages of biopharma projects to facilitate informed decision-making.
Endpoint Outcomes's top competitors include Indegene, IntegriChain and ClearView Healthcare Partners.
Endpoint Outcomes has 1 investor. Key investors include Lumanity.
Yes. Endpoint Outcomes was acquired by Lumanity in June 2022.